Maximon

Maximon operates as a company builder, not a conventional venture capital fund. It creates new ventures internally, provides the corporate setup, seed and Series A funding of up to CHF 10 million, and embeds temporary co-founders and back-office staff from its own team. The firm retains legal and operational control within a unified legal and tax structure until exit.

Maximon builds its own companies from scratch. The firm's model centers on developing science-based longevity concepts internally before incorporating them as new entities, rather than backing external management teams through minority equity stakes. Its website lists portfolio companies AVEA and Frieda Health as examples of ventures it constructed and operated.

Maximon offers access to an in-house scientific advisory board that includes Dr. Brian Kennedy, a researcher at the National University of Singapore, and Prof. Dr. Evelyne Yehudit Bischof, a physician-scientist. The firm also supplies study-design support and facilitates cooperation across its portfolio for shared scientific insight.

The firm's primary sourcing channel is its owned Longevity Investors Conference, an event that gathers researchers, founders, and investors in the longevity space. Combined with its advisory network and European research-campus relationships, the conference serves as both a proprietary origination pipeline and a brand-building platform.

The founding partners—Dr. Tobias Reichmuth, Marc P. Bernegger, Jörg Rieker, and Caroline Wagner—lead investment decisions. They are supported by an operating partner, a head of finance, and a lead venture builder who manage the shared-services layer each new company requires.